• No se han encontrado resultados

Efficacy of telaprevir based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

N/A
N/A
Protected

Academic year: 2020

Share "Efficacy of telaprevir based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C"

Copied!
12
0
0

Texto completo

Loading

Figure

Table 1. Baseline patient characteristics for all patients, by immunosuppressant regimen and overall.
Figure 1.Figure 1.Figure 1.Figure 1.Figure 1.

Referencias

Documento similar

This study evaluated the usefulness of baseline FibroScan values for predicting SVR and the occurrence of anemia and other severe adverse events in HCV genotype 1 patients with

Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Plasminogen activator inhibitor-1

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in

Core tip: The Milan criteria for liver transplantation have improved survival of patients with small hepatocellular carcinoma (HCC), but up to 20% of patients still experience

Antiviral activity of Polyanionic Carbosilane Dendrimers as hepatitis C virus entry inhibitors. (Manuscript

Integrated HIV DNA was quantified by q-PCR in cross- sectional samples from different groups of patients: (1) HIV+ group: HIV-monoinfected patients that had never been in contact

We have evaluated the performance of a deep-sequencing-based HCV subtyping assay, developed for the 454/GS-Junior platform, in comparison with those of two commercial assays

En el caso de pacientes naïve y recidivantes sin cirrosis y ARN-VHC indetectable en la semana cuatro y doce de tratamiento, PEG-IFN y RBV podrán ser suspendidos en la semana